Tandem Diabetes Care (Nasdaq:TNDM) announced today that it launched Tandem Source, a diabetes management platform.
The platform, for both insulin pump users and healthcare providers, brings together features of Tandem Diabetes Care’s legacy offerings. It combines t:connect, t:connect HCP and t:connect Portal with new, comprehensive data reporting in one central, scalable platform.
All Tandem pump users and their providers can access Tandem Source in the U.S. The company expects international availability in 2024.
Tandem Source provides access to important therapy data and ways for users to reorder supplies and update pump software. For providers, it offers the tools necessary to seamlessly view critical patient data, identify trends and help patients manage their diabetes. Both providers and users have access to three new Tandem Source reports within the platform.
“The launch of Tandem Source offers new, easy-to-use reports and the consolidation of several platforms and features into a single, convenient location for all our customers’ needs,” John Sheridan, president and CEO of Tandem Diabetes Care, said in a news release. “Feedback from early adopters of Tandem Source in the United States has been overwhelmingly positive, and we look forward to expanding access to other countries in the coming year.”
More on Tandem Source and another milestone at Tandem Diabetes Care
Other highlights of Tandem Source include a new web-based pump uploader. This offers faster data transfers to the cloud with no computer software to install or update.
The system also automatically transfers data from users’ pumps using the t:connect mobile app. These transfers keep online data current and remove the need for manual pump uploads.
With the three easy-to-use reports, all information needed for providers to make impactful clinical recommendations is consolidated within the platform. All users of the t:connect Portal or t:connect HCP will have data automatically transferred to Tandem Source. They can use their existing login credentials.
This announcement marks the latest positive step in a year full of good news for Tandem Diabetes Care.
Before that, Tandem Diabetes Care reported positive clinical data for its t:slim X2 artificial pancreas technology. The company also received FDA clearance for its new Mobi insulin patch pump technology earlier this year.